SCHEMBL2353665

SCHEMBL2353665

COc1cc(-c2cnn(C)c2)cn2ncc(CNc3ccc(N)cc3)c12

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 1/20 0.44
KDR P35968 1/20 0.44
RET P07949 12/20 0.38
AAK1 Q2M2I8 1/20 0.38
PIK3CD O00329 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CG P48736 2/20 0.37
ERN1 O75460 1/20 0.36
NTRK1 P04629 2/20 0.35
CSF1R P07333 2/20 0.35
NTRK2 Q16620 2/20 0.35
NTRK3 Q16288 1/20 0.35
ACVR2A P27037 1/20 0.35
PIK3CB P42338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13509608 0.91 FGFR3 (0.44) FGFR3KDRRETAAK1PIK3CD
SCHEMBL2353033 0.86 RET (0.45) FGFR3KDRRETPIK3CDPIK3CA
SCHEMBL2354627 0.86 FGFR3 (0.44) FGFR3KDRRETACVR2A
SCHEMBL1906737 0.85 FGFR3 (0.41) FGFR3KDRRETERN1ACVR2A
SCHEMBL2350172 0.85 FGFR3 (0.44) FGFR3KDRRETAAK1ERN1
SCHEMBL1906149 0.84 LRRK2 (0.42) FGFR3KDRRET
SCHEMBL1908240 0.83 FGFR3 (0.44) FGFR3KDRRETACVR2A
SCHEMBL2355340 0.83 FGFR3 (0.46) FGFR3KDRRETNTRK1NTRK2
SCHEMBL1907552 0.83 RET (0.45) FGFR3KDRRET
SCHEMBL2353690 0.82 GAA (0.49) FGFR3KDRNTRK1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US claimed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US claimed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 FGFR3 35/4885KDR 1534/4885RET 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.